REGENXBIO flags going concern as cash runs to early 2027; RGX-202 pivots, RGX-121 stalls

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read

Key Changes

• high

  Company discloses substantial doubt about ability to continue as a going concern, with $150.5M cash runway into early 2027—down from $272.7M a year ago. Operating cash burn hit $76.2M in Q1 2026 vs. $33.6M inflow in Q1 2025.

  MD&A: Liquidity verify on EDGAR →
• high

  RGX-202 met primary endpoint in pivotal trial (93% of patients achieved microdystrophin expression >10%, p<0.0001), but FDA recommended randomized controlled trial despite company's plan to pursue accelerated approval for 2027 launch.

  MD&A: RGX-202 Development verify on EDGAR →
• high

  FDA issued Complete Response Letter for RGX-121 in February 2026, citing uncertainty about eligibility criteria, external control comparability, and surrogate endpoint validity. Company filed Formal Dispute Resolution Request; outcome uncertain.

  MD&A: RGX-121 Regulatory verify on EDGAR →